EIF2AK3 and gastric cancer: Based on our data, we propose that relatively high pERK protein in GC tumors is a potential marker of resistance to DIACC3010 and a reduction in pERK levels, upon treatment with DIACC3010 combined with trastuzumab, is a potential response marker for the combination.